Real-world management of treatment-naïve diabetic macular oedema: 2-year visual outcome focusing on the starting year of intervention from STREAT-DMO study.
Masahiko ShimuraShigehiko KitanoDaisuke MuramatsuHarumi FukushimaYoshihiro TakamuraMakiko MatsumotoMasahide KokadoJiro KogoMariko SasakiYuki MorizaneTakuya UtsumiTakashi KotoShozo SonodaTakao HiranoHiroto IshikawaYoshinori MitamuraFumiki OkamotoTakamasa KinoshitaKazuhiro KimuraMasahiko SugimotoKenji YamashiroYukihiko SuzukiTaiichi HikichiNoriaki WashioTomohito SatoKishiko OhkoshiHiroki TsujinakaSentaro KusuharaMineo KondoHitoshi TakagiToshinori MurataTaiji Sakamotonull nullPublished in: The British journal of ophthalmology (2020)
For recent years, treatment patterns for DMO have been gradually but certainly changed; as a result, better visual gain, suppression of worsened eyes and better final BCVA have been obtained. Anti-VEGF therapy has become the first-line therapy and its injection frequency has been increasing.
Keyphrases